Abbott Laboratories $ABT Holdings Raised by Voya Investment Management LLC

Abbott Laboratories logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Voya Investment Management increased its Abbott stake by 665.2% in the third quarter, adding about 2.8 million shares and bringing its holdings to 3.22 million shares, valued at roughly $318.6 million.
  • Abbott reported quarterly earnings of $1.42 per share, matching estimates, while revenue of $13.01 billion slightly beat expectations and rose 14.5% year over year.
  • Analysts’ consensus rating is “Moderate Buy,” with an average price target of $118.32; Abbott also pays an annualized dividend of $2.52 per share, a 2.4% yield.
  • Five stocks we like better than Abbott Laboratories.

Voya Investment Management LLC grew its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 665.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,224,177 shares of the healthcare product maker's stock after buying an additional 2,802,830 shares during the period. Voya Investment Management LLC owned 0.19% of Abbott Laboratories worth $318,646,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Farther Finance Advisors LLC grew its holdings in Abbott Laboratories by 14.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 84,377 shares of the healthcare product maker's stock valued at $8,339,000 after buying an additional 10,431 shares in the last quarter. Juncture Wealth Strategies LLC bought a new stake in Abbott Laboratories in the 3rd quarter worth approximately $658,000. Aureus Asset Management LLC raised its holdings in shares of Abbott Laboratories by 25.0% during the 1st quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker's stock worth $34,078,000 after acquiring an additional 66,422 shares in the last quarter. Thompson Investment Management Inc. raised its holdings in shares of Abbott Laboratories by 786.0% during the 2nd quarter. Thompson Investment Management Inc. now owns 14,061 shares of the healthcare product maker's stock worth $1,276,000 after acquiring an additional 12,474 shares in the last quarter. Finally, Clear Harbor Asset Management LLC bought a new position in shares of Abbott Laboratories during the 2nd quarter valued at approximately $4,889,000. Hedge funds and other institutional investors own 75.18% of the company's stock.

Insider Transactions at Abbott Laboratories

In related news, EVP Mary Moreland sold 3,500 shares of the firm's stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $116.00, for a total value of $406,000.00. Following the completion of the sale, the executive vice president directly owned 100,791 shares in the company, valued at $11,691,756. This trade represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.46% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Wall Street Zen raised shares of Abbott Laboratories from a "hold" rating to a "buy" rating in a report on Saturday, October 24th. UBS Group decreased their price target on shares of Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating on the stock in a research note on Tuesday, July 28th. Wolfe Research upgraded shares of Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 price objective for the company in a research report on Thursday, August 13th. Wells Fargo & Company lifted their price objective on shares of Abbott Laboratories from $112.00 to $119.00 and gave the stock an "overweight" rating in a research note on Thursday, October 22nd. Finally, BTIG Research reduced their target price on shares of Abbott Laboratories from $134.00 to $125.00 and set a "buy" rating on the stock in a report on Thursday, October 22nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $118.32.

View Our Latest Research Report on Abbott Laboratories

Abbott Laboratories Trading Down 2.6%

Shares of ABT stock opened at $104.64 on Wednesday. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $132.02. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.45 and a quick ratio of 1.00. The stock's 50 day simple moving average is $103.89 and its two-hundred day simple moving average is $101.74. The company has a market cap of $181.23 billion, a PE ratio of 39.04, a price-to-earnings-growth ratio of 1.88 and a beta of 0.54.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, hitting analysts' consensus estimates of $1.42. The firm had revenue of $13.01 billion during the quarter, compared to analysts' expectations of $12.99 billion. Abbott Laboratories had a return on equity of 18.04% and a net margin of 9.75%. The company's quarterly revenue was up 14.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.30 EPS. Research analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, November 16th. Investors of record on Thursday, October 15th were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.4%. The ex-dividend date was Thursday, October 15th. Abbott Laboratories's dividend payout ratio is presently 94.03%.

About Abbott Laboratories

(Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott's offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.

Featured Stories

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Abbott Laboratories Right Now?

Before you consider Abbott Laboratories, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.

While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines